SOMAVERT Drug Profile

Summary for Tradename: SOMAVERT

High Confidence Patents:	1
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for SOMAVERT
Recent Clinical Trials:	See clinical trials for SOMAVERT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SOMAVERT

See drug prices for SOMAVERT

Recent Clinical Trials for SOMAVERT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
St. Michael's Hospital, Toronto	Phase 3
Unity Health Toronto	Phase 3
Novartis	Phase 4

See all SOMAVERT clinical trials

Recent Litigation for SOMAVERT

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Sight Sciences, Inc. v. Ivantis, Inc.	2021-09-16
Trutek Corp. v. BlueWillow Biologics, Inc.	2021-02-10
Supernus Pharmaceuticals, Inc v. Actavis Inc.	2016-02-23

See all SOMAVERT litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SOMAVERT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SOMAVERT Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	5,849,535	2015-09-21	Company disclosures

3) Low Certainty: US Patents for SOMAVERT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	10,111,968	2032-02-15	Patent claims search
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	10,112,021	2026-06-08	Patent claims search
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	10,182,561	2024-12-29	Patent claims search
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	10,214,540	2032-07-03	Patent claims search
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	10,656,152	2029-01-29	Patent claims search

International Patents for SOMAVERT

Country	Patent Number	Estimated Expiration
Japan	2002119294
Japan	2005065705
Canada	2658039
Japan	H04502454
Netherlands	300210

Supplementary Protection Certificates for SOMAVERT

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
91204	Luxembourg		91204, EXPIRES: 20171113
132006901381900	Italy		AUTHORISATION NUMBER(S) AND DATE(S): EU/1/02/240/001-003, 20021113
122006000003	Germany		PRODUCT NAME: WIRKSTOFFZUSAMMENSETZUNG UMFASSEND PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113
05C0043	France		PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113
43/2005	Austria		PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001 - 003 20021113

Market Dynamics and Financial Trajectory for the Biologic Drug: SOMAVERT

Introduction

SOMAVERT, a prescription medicine used to treat acromegaly in patients whose disease has not been controlled by surgery or radiation, is a significant player in the biologic therapeutic drugs market. Here, we will delve into the market dynamics and financial trajectory of SOMAVERT, highlighting key trends, growth prospects, and financial performance.

Market Overview

The global market for biologic therapeutic drugs is experiencing robust growth, driven by the increasing need for effective treatments for complex diseases. SOMAVERT, developed by Pfizer, is part of this larger market segment.

Global Biologic Therapeutic Drugs Market

The global market for biological therapeutic drugs is projected to grow from $452.9 billion in 2023 to $823.4 billion by 2028, with a CAGR of 12.7% during the forecast period of 2023-2028[4].

SOMAVERT Market Size and Growth

Current Market Size

As of 2023, the global SOMAVERT drugs market was valued at US$ 268 million[1].

Forecasted Growth

The market is anticipated to reach US$ 331.5 million by 2030, witnessing a CAGR of 3.1% during the forecast period of 2024-2030. This growth is driven by the increasing prevalence of acromegaly and the need for effective treatment options[1].

Market Segmentation

By Type

The SOMAVERT market is segmented into prefilled and non-prefilled types. The prefilled segment is gaining traction due to its convenience and ease of use[1].

By Application

The primary applications of SOMAVERT include hospitals and pharmacies. The hospital segment is dominant due to the need for close medical supervision during treatment[1].

Competitive Landscape

Key Players

Pfizer is the main player in the SOMAVERT market. The company's strong research and development capabilities, along with its extensive distribution network, contribute to its market dominance[1].

Financial Performance of Pfizer

Overall Revenue

Pfizer's full-year 2023 revenues totaled $58.5 billion, a decrease of 42% compared to 2022, primarily due to the decline in revenues from COVID-19 products like Comirnaty and Paxlovid. However, excluding these products, Pfizer's revenues grew 7% operationally[2].

Segment Performance

The biopharmaceutical segment, which includes SOMAVERT, saw operational revenue growth driven by new product launches and indications. For example, Abrysvo contributed $515 million in global revenues in the fourth quarter of 2023, highlighting the potential for growth in Pfizer's biopharmaceutical portfolio[2].

Cost Savings and Efficiency

Pfizer is on track to deliver at least $4 billion in annual net cost savings by the end of 2024 from its previously announced cost realignment program. This initiative is expected to improve operational efficiency and margin improvement, which could positively impact the financial trajectory of SOMAVERT and other biologic drugs[2].

Market Drivers

Increasing Prevalence of Acromegaly

The growing prevalence of acromegaly and the need for effective treatments are key drivers of the SOMAVERT market. As awareness and diagnosis rates improve, the demand for SOMAVERT is expected to increase[3].

Advancements in Biologic Therapeutics

Advancements in biologic therapeutic drugs, including improvements in manufacturing technologies and the development of new indications, are driving growth in the market. These advancements make biologic drugs like SOMAVERT more accessible and effective[4].

Challenges and Opportunities

Regulatory Environment

The regulatory environment plays a crucial role in the biologic drugs market. Stringent regulations and the need for continuous compliance can pose challenges but also ensure the safety and efficacy of drugs like SOMAVERT[4].

Competitive Market

The biologic therapeutic drugs market is highly competitive, with several players vying for market share. Pfizer's strong brand and research capabilities help SOMAVERT maintain its market position, but continuous innovation is necessary to stay competitive[4].

Key Takeaways

• The SOMAVERT market is valued at US$ 268 million in 2023 and is expected to reach US$ 331.5 million by 2030, with a CAGR of 3.1%.
• Pfizer is the main player in the SOMAVERT market.
• The market is driven by the increasing prevalence of acromegaly and advancements in biologic therapeutics.
• Pfizer's overall revenue and operational efficiency initiatives are crucial for the financial trajectory of SOMAVERT.

FAQs

What is SOMAVERT used for?

SOMAVERT is a prescription medicine used to treat acromegaly in patients whose disease has not been controlled by surgery or radiation[3].

Who is the main player in the SOMAVERT market?

Pfizer is the main player in the SOMAVERT market[1].

What is the forecasted growth rate of the SOMAVERT market?

The SOMAVERT market is expected to grow at a CAGR of 3.1% from 2024 to 2030[1].

What are the key drivers of the SOMAVERT market?

The key drivers include the increasing prevalence of acromegaly and advancements in biologic therapeutic drugs[3][4].

How does Pfizer's overall financial performance impact SOMAVERT?

Pfizer's overall revenue and cost-saving initiatives can positively impact the financial trajectory of SOMAVERT by improving operational efficiency and margin improvement[2].

Sources

1. Valuates Reports: Global Somavert Drugs Industry Report.
2. Pfizer: Q4 2023 Earnings Release.
3. SOMAVERT: Prescription Information.
4. BCC Research: Biologic Therapeutic Drugs: Technologies and Global Markets Report.